NRXP — NRX Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $107.81m
- $81.53m
- $1.23m
U.S. STOCKS ON THE MOVE-Horizon Global, Apple, PayPal Holdings
NRX Pharma rises on start to late-stage study of bipolar disorder drug
Brief: NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients With Bipolar Depression Acute Suicidality
Brief: NRx Pharmaceuticals Announces The Appointment Of Carrie M. Carretta, Senior Vice President Of Clinical Development And Medical Affairs
Brief: Nrx Receives Nasdaq Notice Of Listing Compliance
Drug developer NRX up on smaller third-quarter loss
Brief: Nrx Pharmaceuticals Reports Q3 2022 Financial Results
Brief: Relief Therapeutics Holding And Nrx Pharmaceuticals Announce Execution Of Definitive Settlement Agreements
NRX Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Nrx Pharmaceuticals Produces First Phase 3-Stage Nrx-101 Drug Made Using Commercial Process
Brief: Relief Therapeutics And NRX Announce Tentative Settlement Of Pending Litigation
U.S. STOCKS ON THE MOVE-Unity Software, Cardinal Health, Tesla
U.S. STOCKS ON THE MOVE-AEye, Team, Moderna, Snap
NRX Pharma up on plans to start second psychiatry study
Brief: NRx Pharmaceuticals Reports Q2 Net Loss Of $7.0 Million Compared With A Net Loss Of $0.1 Million
Brief: Nrx-Accounting For Features Of Substitute Warrants Issued May 24, 2021 In Merger Deal With Big Rock Partners Acquisition For Affected Periods Incorrect
NRX Pharmaceuticals Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: NRX Pharma Receives Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Nrx Pharmaceuticals Appoints Stephen Willard As CEO